RGX 202Alternative Names: RGX-202
Latest Information Update: 23 Jun 2016
At a glance
- Originator Rgenix
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 15 Jun 2016 Preclinical trials in Cancer in USA (unspecified route) prior to June 2016
- 15 Jun 2016 Rgenix plans a phase I trial for Cancer in USA (Rgenix website, June 2016)